# Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects

> **NCT00812305** · PHASE1 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 16 (actual)

## Conditions studied

- Pain
- Hepatic Impairment

## Interventions

- **DRUG:** SKY0402 300mg in healthy patients
- **DRUG:** SKY0402 300mg in hepatically impaired patients

## Key facts

- **NCT ID:** NCT00812305
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2010-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00812305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00812305, "Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00812305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*